andresr/E+ via Getty Images LENZ Therapeutics ( NASDAQ: LENZ ) and Corxel Pharmaceuticals reported positive Phase 3 data from a study in China of the drug LNZ100 in the treatment of presbyopia, also known as far-sightedness. The companies said the study’s primary endpoint was met with 74% of.
Back to Health Page
